Switching from Rybelsus to Wegovy: the conversion explained

Why Rybelsus and Wegovy are not interchangeable, despite sharing the same molecule

Both products carry semaglutide on the label, which is why the question of switching comes up so often. A question our prescribers hear most weeks is whether someone can simply "convert" their Rybelsus dose to a Wegovy equivalent. The honest answer is that the two medicines were designed for distinct clinical situations, and the comparison is messier than it first appears.

Rybelsus tablets come in 3 mg, 7 mg and 14 mg strengths. Those numbers belong to its diabetes licence, they represent a titration schedule built around blood-sugar management, not appetite regulation or weight loss. The 7 mg Rybelsus tablet, for instance, sits at a dose that does not map neatly onto any Wegovy injection dose, and it certainly does not correspond to a step on the oral Wegovy weight-loss ladder (which runs 1.5 mg, 4 mg, 9 mg and 25 mg). Comparing the milligram figures between the two products risks misleading conclusions.

There is also a pharmacokinetic difference. Oral semaglutide is absorbed in conditions that favour its formulation, taken first thing on an empty stomach with a small amount of plain water, with a 30-minute fast before anything else. Semaglutide injected subcutaneously bypasses that absorption step entirely and reaches systemic levels differently. So even if the dose numbers aligned, the clinical effect would not be equivalent unit for unit. The MHRA licences each formulation on the basis of its own trial evidence; the NHS medicines page for semaglutide sets this out clearly.

What actually drives the decision to switch

The reasons someone might consider moving from Rybelsus to a Wegovy product are usually one of three things: their diabetes management is now being handled differently (perhaps they have moved to another medicine or achieved remission), they want to focus on weight management rather than glycaemic control, or their prescriber is reviewing whether the current treatment is still the best fit.

Each of those reasons leads to a genuinely different clinical conversation. If diabetes is still active, stopping Rybelsus without a replacement for blood-sugar control is not straightforward, your GP or diabetes team needs to be involved. If weight management is the goal, a prescriber would assess whether you meet the eligibility criteria for Wegovy (BMI of 30 or above, or 27 or above with at least one weight-related health condition) and decide which formulation suits you: the weekly injection or the daily oral tablet, approved by the MHRA in June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK.

Worth noting: people who are already established on the 2.4 mg weekly Wegovy injection may be able to transition to the 25 mg oral tablet without restarting the full titration ladder, subject to prescriber assessment. That route exists; a direct jump from Rybelsus to the 25 mg tablet does not, because Rybelsus is a diabetes medicine and no such equivalence is established in the licences.

What IS licensed for weight management in the UK, and what that means for you

If weight loss is the reason you are exploring this switch, it helps to be clear about what the UK licences actually cover. Wegovy (semaglutide injection and, since June 2026, the oral weight-loss tablet) and Mounjaro (tirzepatide injection) are the two medicines licensed specifically for weight management by the MHRA. Rybelsus is not. If a provider were to prescribe Rybelsus for weight loss, that would be off-label, not automatically dangerous, but a different clinical and regulatory position from a licensed weight-management medicine.

The distinction matters because the evidence base, prescribing guidance and safety monitoring all follow the licence. NICE's appraisal of semaglutide for weight management (TA875) assessed Wegovy's injection, not Rybelsus. The emerging evidence for oral semaglutide in weight management is built on the Wegovy tablet's own trial programme, not on Rybelsus data. If you are wondering whether there is a pill version of Wegovy and how it differs from Rybelsus, our dedicated page covers the background, the MHRA approval, and what it means in practice. If you are curious how the two semaglutide delivery routes compare for weight loss, our page on whether Rybelsus is as effective as Wegovy walks through the evidence gap honestly.

For those looking at the broader landscape of oral options, the semaglutide tablets guide covers the distinction between the Rybelsus and Wegovy tablet products in detail. And if you are thinking about where the oral Wegovy tablet fits into the wider picture of weight-loss treatment available in the UK, the weight-loss treatments overview is a practical starting point.

A clinical assessment is the only way to work out which medicine, which formulation, and which starting dose is appropriate for your situation. num prescribers review each consultation personally (no automated decisions) and can help you understand your options if you are considering a licensed weight-management route.